The Biology of Cellular Senescence
Cellular senescence is a state of stable, permanent cell cycle arrest that differs fundamentally from quiescence (reversible arrest) and apoptosis (programmed cell death). Senescent cells are metabolically active — they continue to transcribe genes, secrete proteins, and respond to signals — but they cannot divide. This distinction is critical: senescent cells are not dead cells, and their active secretory program (the SASP) is what makes them toxic to the surrounding tissue.
Two Primary Senescence Pathways
Replicative senescence (p16/Rb pathway): As cells divide over a lifetime, telomeres shorten with each replication cycle. When telomeres reach a critically short length, they are recognized as DNA double-strand breaks by the DDR (DNA damage response) machinery. This activates ATM/ATR kinases → p53 → p21 (initial arrest), and subsequently upregulates p16^INK4a, which inhibits CDK4/6 — preventing phosphorylation of the retinoblastoma protein (Rb) and locking the cell permanently in G1 phase. The p16-Rb axis is the dominant pathway in replicative senescence and is the most widely used biomarker (p16 expression).
Stress-induced premature senescence (SIPS — p21/p53 pathway): Oncogene activation (e.g., activated RAS), oxidative stress, chemotherapy, radiation, and other stressors trigger senescence via p53 → p21 independently of telomere length. This is "oncogene-induced senescence" (OIS) — a tumor-suppressive mechanism that arrests potentially malignant cells before they can proliferate. The paradox: while senescence initially prevents tumor formation, the subsequent SASP can create a pro-tumorigenic microenvironment for neighboring cells ("bystander effect").
The SASP: Why Senescent Cells Are Toxic
The senescence-associated secretory phenotype (SASP) is a complex, NF-κB- and C/EBPβ-driven transcriptional program that produces:
- Pro-inflammatory cytokines: IL-6, IL-8, IL-1α, IL-1β, GM-CSF — which activate NF-κB in neighboring cells, creating a feedforward inflammatory loop. IL-6 from senescent cells drives STAT3 activation and has been directly linked to sarcopenia, insulin resistance, and cognitive decline.
- Matrix metalloproteinases (MMPs): MMP-1, MMP-3, MMP-10, MMP-13 — degrade extracellular matrix components (collagen, elastin), disrupting tissue architecture. The skin wrinkles, lung parenchyma collapses (emphysema/fibrosis), and joint cartilage degrades — all show evidence of SASP-driven MMP activity as the proximate mechanism.
- Growth factors: VEGF (promotes angiogenesis), EGF, HGF — which can stimulate proliferation of neighboring pre-malignant cells, contributing to cancer risk with aging.
- SASP factors promote "paracrine senescence": SASP from senescent cells can induce senescence in neighboring non-senescent cells via secreted IL-1α, TGF-β, and reactive oxygen species — creating exponentially spreading senescence clusters in aged tissue.
Senolytic Mechanisms: How Different Agents Kill Senescent Cells
Senescent cells upregulate pro-survival pathways that protect them from apoptosis — this is why they persist despite being damaged and growth-arrested. Senolytics exploit these pathways:
BCL-2/BCL-XL Pathway (Navitoclax, Venetoclax)
Senescent cells upregulate anti-apoptotic BCL-2 family proteins (BCL-2, BCL-XL, BCL-W) that sequester pro-apoptotic proteins (BAX, BAK, BIM). Navitoclax (ABT-263) is a BH3 mimetic that competitively displaces pro-apoptotic proteins from BCL-2 and BCL-XL — releasing them to activate the mitochondrial apoptosis pathway. In senescent cells that depend heavily on BCL-2/XL for survival, this triggers selective cell death. The major limitation: platelets depend on BCL-XL for survival, making navitoclax cause thrombocytopenia (low platelet count) at doses required for senolysis. Second-generation agents (A1331852, BCL-XL-specific; UBX0101, MDM2 inhibitor) are in clinical development to improve the therapeutic window.
PI3K/AKT Survival Pathway (Quercetin, Fisetin)
Senescent cells also upregulate the PI3K/AKT/mTOR survival axis. Quercetin and fisetin inhibit PI3K isoforms and reduce AKT phosphorylation in senescent cells more effectively than in non-senescent cells — the basis of their selective senolytic activity. Quercetin also inhibits serpine 1 (PAI-1) and BCL-XL at high concentrations. Fisetin proved more potent than quercetin, apigenin, luteolin, kaempferol, myricetin, resveratrol, curcumin, catechin, and rutin in the Zhu 2017 flavonoid screen.
Dasatinib's Mechanism in Senolysis
Dasatinib is an FDA-approved BCR-ABL and Src-family kinase inhibitor used in chronic myeloid leukemia (CML). Its senolytic activity was identified by Kirkland's group in a computational screen that predicted dasatinib would inhibit ephrin receptors and other tyrosine kinases upregulated in fat cell progenitor senescence. Dasatinib's senolytic targets include EPHA2, EPHA5, and other receptor tyrosine kinases that are part of the senescent cell survival network. The D+Q combination is synergistic because dasatinib targets fat cell-derived senescent cells while quercetin is more effective against endothelial and hematopoietic senescent cells — the two agents cover complementary senescent cell subtypes.
| Senolytic Agent | Mechanism | Strongest Evidence | Human Status |
|---|---|---|---|
| Dasatinib + Quercetin (D+Q) | Dasatinib: Src/ephrin kinase inhibition; Quercetin: PI3K/AKT inhibition + BCL-XL inhibition; synergistic coverage of distinct senescent cell types | Kirkland 2019 (EBioMedicine): reduced p16+ cells in adipose biopsy, reduced SASP cytokines, improved physical function in IPF; multiple subsequent small trials in diabetic kidney disease, osteoporosis | Multiple completed Phase 1/2 trials; SENolytic Therapy to Modulate Progress of Alzheimer's Disease (SToMP-AD) trial ongoing; considered investigational outside trials |
| Fisetin | PI3K/AKT survival pathway inhibition; most potent in flavonoid screen; also activates SIRT1 and has anti-inflammatory properties independent of senolysis | Zhu 2017 (EBioMedicine): most potent natural senolytic in 10-compound screen; multiple mouse aging/lifespan studies positive; human RCT (AFFIRM-LITE, Mayo Clinic) completed — results published showing reduction in senescent cell markers in older adults | AFFIRM-LITE human trial completed; considered most accessible natural senolytic; doses used in mouse studies far exceed typical supplement doses (20–100mg/kg) |
| Navitoclax (ABT-263) | BCL-2/BCL-XL BH3 mimetic; most potent senolytic identified; selectively kills senescent cells dependent on BCL-XL for survival | Chang 2016 (Nat Med): navitoclax cleared senescent cells and reversed lung fibrosis in mice; Strong 2021: improved multiple aging phenotypes; most potent mechanism of any senolytic studied | Clinical use limited by thrombocytopenia (platelet BCL-XL dependence); not used outside oncology. Second-gen BCL-XL-specific agents (navitoclax analogs) in active development to avoid platelet toxicity |
| UBX0101 (MDM2 inhibitor) | Inhibits MDM2 → stabilizes p53 → apoptosis in senescent cells; joint-specific delivery by intra-articular injection avoids systemic side effects | Positive mouse OA data; Phase 2 human trial in knee osteoarthritis completed (Unity Biotechnology) — did not meet primary endpoint at 12 weeks but showed signals in subgroup analyses; trial design criticized for short duration | Phase 2 completed; Unity Biotechnology pivoted to eye disease applications (subretinal UBX1325 for AMD/DME — showing more promise) |
Senolytic and Senomorphic Approaches: What's Evidence-Based Without a Prescription
- Fisetin — the most accessible natural senolytic: The Zhu 2017 screen identified fisetin as the most potent natural senolytic among 10 tested flavonoids. The AFFIRM-LITE trial (Mayo Clinic) used 20mg/kg for 2 consecutive days (a "pulse" approach mirroring D+Q's pulsed protocol). For a 70kg adult, that's 1,400mg/day for 2 days. Most commercial fisetin supplements are 100–500mg capsules. The logic for pulsed high-dose (vs daily low-dose) is that senolytics work acutely — you need sufficient drug exposure to drive senescent cells past their apoptotic threshold, then let normal cells recover. A monthly 2-day "fisetin pulse" at 1–2g/day is the most common protocol derived from clinical trial dosing, though no human RCT has yet validated an optimal pulse schedule.
- Quercetin as a senomorphic (SASP suppressor) at daily doses: At lower doses (500–1,000mg/day), quercetin may act as a senomorphic — reducing SASP cytokine secretion from senescent cells without necessarily killing them. This is lower-stakes than high-dose pulsed senolysis and supported by quercetin's anti-inflammatory mechanism (NF-κB inhibition). Quercetin with bromelain (pineapple enzyme that improves quercetin absorption) or as quercetin phytosome is recommended for bioavailability — plain quercetin aglycone has poor absorption (~17% from supplements).
- Exercise as a senomorphic and senolytic stimulus: Regular aerobic exercise reduces circulating SASP markers (IL-6, CRP, TNF-α) and has been shown in animal models to reduce p16+ senescent cell burden in muscle and liver. The mechanism is partially via autophagy (which degrades senescent cells) and partially via immune surveillance activation — natural killer (NK) cells clear senescent cells, and exercise activates NK cell cytotoxicity. A sedentary lifestyle is one of the most powerful promoters of senescent cell accumulation; regular moderate exercise is one of the most powerful non-pharmacological senomorphic interventions.
- Senescence biomarkers currently accessible: There is no perfect blood test for senescent cell burden. Available proxies: (1) Serum p16^INK4a expression in peripheral blood T-cells (offered by some longevity clinics); (2) High-sensitivity CRP, IL-6, and MMP-3 as SASP surrogates (though non-specific); (3) GrimAge epigenetic clock acceleration (measures biological aging, partially driven by senescence). These are research-grade, not clinically validated diagnostic tools. Tracking SASP cytokines before and after a senolytic protocol is used in clinical trials to confirm biological activity.
- Dasatinib + Quercetin — prescription only, investigational context: D+Q (dasatinib 100mg + quercetin 1,000mg for 3 consecutive days, repeated monthly or quarterly) is used off-label by some longevity-focused physicians. Dasatinib is FDA-approved for CML at 100mg/day — the same dose used in senolytic protocols. Risks include dasatinib's side effect profile (fluid retention, QT prolongation, cytopenias at higher doses), and the protocol requires physician oversight and monitoring. Do not attempt D+Q without medical supervision.
Fisetin (from Rhus succedanea extract, ~98% purity) is available in 100–500mg capsules. For senolytic pulse protocols informed by AFFIRM-LITE trial methodology (20mg/kg x 2 days/month), a 70kg individual would target ~1,400mg/day x 2 days. Look for products with standardized fisetin content (not just "plant extract") and third-party testing. NOW Foods, DoNotAge, and ProHealth Longevity offer tested products. Store in a cool, dark place — fisetin is light-sensitive.
Plain quercetin has poor absorption (~17% bioavailability). Quercetin phytosome (Quercefit) and quercetin with bromelain improve absorption 20-fold. For senomorphic (daily SASP suppression) use: 500mg quercetin phytosome with food. For senolytic pulsing alongside fisetin: plain quercetin 1,000mg x 3 days is the D+Q trial protocol dose. Avoid concurrent grapefruit as quercetin inhibits CYP3A4.